 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- ||| ALN-PNP / Alnylam, Regeneron
Enrollment open, Trial completion date, Trial primary completion date: A Trial to Learn if Receiving ALN-PNP siRNA is Safe and Well Tolerated, and How it Works in Adult Participants With Nonalcoholic Fatty Liver Disease (NAFLD) and a Genetic Risk Factor (clinicaltrials.gov) - Jun 19, 2024
P1, N=104, Recruiting, Sponsor: Regeneron Pharmaceuticals
Not yet recruiting --> Recruiting | Trial completion date: Dec 2026 --> Sep 2025 | Trial primary completion date: May 2026 --> Sep 2025
- || ALN-PNP / Alnylam, Regeneron
Enrollment change, Trial completion date, Trial primary completion date: A Trial to Learn if ALN-PNP is Safe and Well Tolerated in Healthy Adults and Adult Participants With Non-Alcoholic Fatty Liver Disease (NAFLD) (clinicaltrials.gov) - Mar 12, 2024
P1, N=96, Recruiting, Sponsor: Regeneron Pharmaceuticals
Not yet recruiting --> Recruiting | Trial completion date: Dec 2026 --> Sep 2025 | Trial primary completion date: May 2026 --> Sep 2025 N=64 --> 96 | Trial completion date: Dec 2023 --> Sep 2025 | Trial primary completion date: Dec 2023 --> Sep 2025
- || ALN-PNP / Alnylam, Regeneron
Trial completion date, Trial initiation date, Trial primary completion date: A Trial to Learn if Receiving ALN-PNP siRNA is Safe and Well Tolerated, and How it Works in Adult Participants With Nonalcoholic Fatty Liver Disease (NAFLD) and a Genetic Risk Factor (clinicaltrials.gov) - Jan 24, 2024
P1, N=104, Not yet recruiting, Sponsor: Regeneron Pharmaceuticals
N=64 --> 96 | Trial completion date: Dec 2023 --> Sep 2025 | Trial primary completion date: Dec 2023 --> Sep 2025 Trial completion date: Jan 2026 --> Dec 2026 | Initiation date: Nov 2023 --> Apr 2024 | Trial primary completion date: Jan 2026 --> May 2026
- ||| ALN-PNP / Alnylam, Regeneron
New P1 trial: A Trial to Learn if Receiving ALN-PNP siRNA is Safe and Well Tolerated, and How it Works in Adult Participants With Nonalcoholic Fatty Liver Disease (NAFLD) and a Genetic Risk Factor (clinicaltrials.gov) - Sep 6, 2023
P1, N=96, Not yet recruiting, Sponsor: Regeneron Pharmaceuticals
- ||| ALN-PNP / Alnylam, Regeneron
Enrollment open: A Trial to Learn if ALN-PNP is Safe and Well Tolerated in Healthy Adults and Adult Participants With Non-Alcoholic Fatty Liver Disease (NAFLD) (clinicaltrials.gov) - Feb 2, 2023
P1, N=64, Recruiting, Sponsor: Regeneron Pharmaceuticals
Trial completion date: Jan 2026 --> Dec 2026 | Initiation date: Nov 2023 --> Apr 2024 | Trial primary completion date: Jan 2026 --> May 2026 Not yet recruiting --> Recruiting
- ||| ALN-PNP / Alnylam, Regeneron
New P1 trial: A Trial to Learn if ALN-PNP is Safe and Well Tolerated in Healthy Adults and Adult Participants With Non-Alcoholic Fatty Liver Disease (NAFLD) (clinicaltrials.gov) - Dec 13, 2022
P1, N=64, Not yet recruiting, Sponsor: Regeneron Pharmaceuticals